Skip to content

A prospective cohort study of acute respiratory failure in idiopathic interstitial pneumonias

A prospective cohort study of acute respiratory failure in idiopathic interstitial pneumonias - AREFIP study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000032940
Enrollment
50
Registered
2018-06-14
Start date
2018-06-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic interstitial pneumonias (IIPs)

Interventions

None listed

Sponsors

Tokai University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pre-existing idiopathic interstitial pneumonia is proved or suspected 2. Acute worsening or development of dyspnea within 1 month 3. Requirement for oxygen therapy to maintain SpO2 >90%, or increase in oxygen flow to maintain SpO2 >90% in cases under long-term oxygen therapy 4. New ground-glass opacity in the lungs on chest computed tomography 5. Written informed consent has been obtained

Exclusion criteria

Exclusion criteria: 1. Connective tissue disease-related interstitial lung disease (CTD-ILD) 2. Hypersensitivity pneumonia 3. Cryptogenic organizing pneumonia 4. Radiation-induced lung injury 5. Pulmonary lymphangitic carcinomatosis 6. Patients who cannot perform the tests conducted in this study

Design outcomes

Primary

MeasureTime frame
1. Proportion and clinical characteristics of IIP cases with acute respiratory failure caused by a factor(s) other than acute exacerbation 2. Clinical characteristics, treatment responses, and prognosis of the patients with acute exacerbation according to a new classification of the severity 3. Clinical characteristics and prognosis of responders and non-responders to glucocorticoid treatment of acute exacerbation 4. Long-term QOL, respiratory function, prevalence of re-exacerbation, and prognosis observation of acute exacerbation survivors 5. Prevalence of acute exacerbation due to specific triggers (drug, surgery, infection, etc.) and their treatment response and prognosis 6. Factors associated with prognosis of acute exacerbation

Countries

Japan

Contacts

Public ContactTakahisa Takihara

Tokai University School of Medicine Division of Pulmonary Medicine, Department of Medicine

ttakihara@gmail.com+81463931121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026